Development of DNA vaccine for Angiotensin II

最近已经开发出疫苗来治疗各种疾病，如癌症、风湿性关节炎和阿尔茨海默病。然而，在临床使用之前，针对自身抗原的疫苗必须证明是有效和安全的，并能引起B细胞的充分体液免疫反应。在这项研究中，我们在小鼠和大鼠身上评估了一种Ang II型疫苗的有效性和安全性。与KLH结合的Ang II免疫成功诱导了抗Ang II抗体的产生。在注入Ang ii的模型中，未免疫小鼠出现高血压（BP），而免疫小鼠（Ang II-KLH）的收缩压明显降低。在DNA疫苗方面，将编码乙型肝炎核心(HBc)- Ang II融合蛋白的质粒载体注射到自发性高血压大鼠（SHR）。HBc-Ang II组成功产生抗ang II抗体，抗体效价维持至少6个月。HBc-Ang II组免疫后收缩压持续降低。

Vaccines have been recently developed to treat various diseases such as cancer, rheumatoid arthritis and Alzheimer’s disease. However, before use in the clinical setting, vaccines targeting self-antigens must be demonstrated to be effective and safe, evoking an adequate humoral immune response from B cells. In this study, we evaluated the efficiency and safety of an Ang II vaccine in mice and rats. Immunization with Ang II conjugated to KLH successfully induced the production of anti-Ang II antibody. In an Ang II-infused model, the non-immunized mice showed high blood pressure (BP), whereas the immunized mice (Ang II-KLH) showed a significant decrease in systolic BP. In terms of DNA vaccine, plasmid vector encoding hepatitis B core (HBc)- Ang II fusion protein was injected into spontaneously hypertensive rats (SHR). Anti-Ang II antibody was successfully produced in HBc-Ang II group, and antibody titers were sustained for at least 6 months. Systolic BP was consistently lower in HBc-Ang II group after immunization.